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Introduction
Disease persistence in chronic phase (CP) chronic myeloid leukaemia (CML) patients on tyrosine kinase inhibitor (TKI) therapy is caused by a population of leukaemic stem cells (LSCs) 1,2 which are not BCR-ABL oncogene addicted 3,4 , thus highlighting the need to identify novel therapeutic targets for their eradication. Autocrine production of interleukin-3 and granulocyte-colony stimulating factor by CML stem/progenitor cells (SPCs) resulting in STAT5 activation and growth factor (GF)-independent growth has been reported suggesting that this mechanism is relevant to BCR-ABL induced transformation 5 . Tumour necrosis factor-alpha (TNF-α) is a pleiotropic GF whose role in haemopoiesis is highly dependent on cell context, its concentration and the presence of other GFs, with both inhibitory and stimulatory effects reported 6-8 . Although originally described as cytotoxic to cancer cells given its ability to induce apoptosis 9 , TNF-α is often produced by malignant and immune cells present in the inflammatory reaction surrounding tumours 10, 11 . Regardless of its source, TNF-α can contribute to tumourigenesis by creating a tumour-supportive inflammatory microenvironment and through direct effects on malignant cells 12 . A role has already been reported for autocrine TNF-α produced by JAK2 V617F+ cells in supporting the growth of myeloproliferative neoplasm patients' CD34 + cells, while inhibiting normal CD34 + cell growth 13 . In CML it has been shown that TNF-α concentration is higher in bone marrow (BM) supernatants derived from BCR-ABL + transgenic compared to wild-type mice.
Moreover LSCs from BCR-ABL + mice proliferate more compared to wild-type counterparts when cultured in the presence of TNF-α at the concentrations detected in the BM of leukaemic mice 14 . More recently, BCR-ABL-mediated upregulation of inflammatory pathway receptors (including TNF-α) has been shown to promote CML LSC self-renewal through upregulation of p150 isoform of the RNA editing enzyme ADAR1 15 . Here we investigated TNF-α production and its putative role as a survival and proliferative signal in primary human CML SPCs.
Materials and methods
Nilotinib (NL) was supplied by Novartis. The small molecule TNF-α inhibitor 16 and human recombinant TNF-α were purchased respectively from Merck Chemicals and New England BioLabs. Plasma and primary cells were obtained following consent, according to the Declaration of Helsinki, from blood and leukapheresis samples of CML and lymphoma patients without BM involvement as normal controls. CD34 + enrichment, in vitro culture in physiologic (for CML cells) or high (for normal cells) GF-supplemented serum-free medium and colony-forming cell (CFC) assays were performed as previously described 3 . Sorting into CD34 + CD38and CD34 + CD38 + cells and detection of BCR-ABL fusion in CD34 + CD38 -CML cells by fluorescence in situ hybridisation were performed as previously reported 17 .
ELISA was carried out using the Invitrogen Human UltraSensitive TNF-α kit (#KHC3014) according to the manufacturer's protocol. Western blotting and flow-cytometry for surface/intracellular protein, annexin and carboxyfluorescein succinimidyl ester (CFSE) staining with percentage recovery calculations were performed as previously described 3,17 .
Quantitative real time-polymerase chain reaction (qRT-PCR) was undertaken using the 
Results and discussion
Having demonstrated that TNF-α plasma levels are consistently higher in CML than normal patients' samples, regardless of disease stage, we investigated TNF-α mRNA expression in a large cohort of CML SPCs and found that it was significantly elevated. Although higher in CML mononuclear compared to CD34 + cells (as expected given TNF-α is normally produced by lymphocytes and macrophages), TNF-α mRNA levels were similar between the CD34 + CD38and CD34 + CD38 + cell fractions ( Figure 1A , B and supplemental Figure 1A , B). We confirmed this finding at the protein level in a small group of samples and showed that autocrine TNF-α production by CML SPCs was not significantly reduced by treatment with NL at either the mRNA or protein level, suggesting that it is not under the control of BCR-ABL kinase ( Figure 1C , D and supplemental Figure 1C -E).
TNF-α's pleiotropic effects are secondary to its ability to activate both proapoptotic and prosurvival signals 18 . Amongst the latter, the NFκB/p65 transcription factor is particularly relevant. Upon NFκB/p65 expression, TNF-α is unable to induce apoptosis because it simultaneously activates NFκB/p65 which promotes, amongst others, the expression of the inhibitor of apoptosis protein (IAP) family. IAPs block the proapoptotic caspase-8 activation also induced by TNF-α so that in their presence the net output of TNF-α signalling is to promote survival and proliferation of its target cells 19, 20 . IAP2 in particular is directly activated by NFκB/p65 and in turn activates it through a positive feedback loop 20 . CML cells express a constitutively active NFκB/p65 21 β -chain receptor (CSF2RB) expression in normal CD34 + cells 23 . We observed that CSF2RB gene and protein expression were higher in CML relative to normal SPCs and downregulated by TNF-α inhibitor, with these effects again rescued by TNF-α (supplemental Figure 3 ). Together these results suggest that autocrine TNF-α could act as a survival and proliferative signal in CML CD34 + by inducing NFκB/p65 activity and CSF2RB expression.
Consistent with this hypothesis, TNF-α inhibitor reduced proliferation and increased apoptosis levels in CML CD34 + cells, including within the TKI resistant quiescent (CFSE max ) population 17, 24 , with TNF-α again rescuing this phenotype (Figure 1G, H) . Similar effects were not seen in normal CD34 + cells which express lower/negligible levels of autocrine TNFα suggesting that the results observed in CML CD34 + cells were secondary to autocrine TNFα inhibition (supplemental Figure 4) .
Because TNF-α production by CML SPCs was not BCR-ABL kinase-dependent and TNF-α inhibitor showed no off-target inhibition of BCR-ABL kinase activity (supplemental Figure   5 ), we investigated the effects of NL and TNF-α inhibitor in combination on CML SPCs.
This combination reduced CML CD34 + cells CFC output and induced significantly higher levels of apoptosis relative to either treatment alone, including within CFSE max and CD34 + CD38cells (Figure 2A -E). Analysis of percentage recovery of starting cells, which relates the contribution of input cells to the surviving output cell number following drug treatment, confirmed that the NL and TNF-α inhibitor combination resulted in a significant depletion of the CFSE max cells relative to untreated ( Figure 2F ).
These observations support the hypothesis that, similarly to the effects reported in JAK2 V617+ myeloproliferative neoplasms 14 , autocrine TNF-α promotes survival and proliferation in CML CD34 + cells and that interference with TNF-α production/signalling could be exploited therapeutically for their eradication. Moreover as TNF-α acts as a prosurvival signal only in the presence of an active NFκB/p65, its autocrine production could also be directed towards apoptosis induction by inhibiting NFκB/p65 signals through IAP inhibitors (such as SMAC mimetics), as already shown in other cancer models 25 . A detailed characterisation of the effects of autocrine GFs produced by CML SPCs can help identifying novel therapeutic targets for their eradication.
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